Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Aricept for Severe AD | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

FDA Approves Aricept for Severe AD

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eisai and Pfizer received FDA approval for an sNDA for Aricept for the treatment of severe Alzheimer’s disease (AD). With this approval, Aricept becomes the only prescription medication to treat mild, moderate and severe AD. Aricept, which is co-promoted in the U.S. by Eisai and Pfizer, has been approved in the U.S. since 1996 for treatment of mild to moderate AD.

The approval was based on results from a multi-center, randomized, double-blind, placebo-controlled trial involving 248 patients with severe AD. Patients treated with Aricept had statistically significant benefit compared to those taking placebo in both primary efficacy measures: the Severe Impairment Battery for cognition and the Modified Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory for Severe Alzheimer’s Disease for function/activities of daily living.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters